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Introduction: Screen detection may confer prognostic benefit
independent of disease stage in EBC leading to suggestions that
mode of presentation should be considered when deciding adju-
vant therapy. We aim to determine if this additional prognostic
benefit is seen in all patients.
Methods: Data from 3 centres in Glasgow of consecutive
women aged between 50 and 65 years with EBC diagnosed
between 1995 and 2001 were examined. Patients were grouped
by mode of presentation into screen detection and symptomatic.
Breast cancer specific survival was the end-point. Multivariate
analysis including interaction between mode of presentation
and pathology was performed with further subgroup analysis if
the interaction was significant.
Results: Women (1534) were included with a median follow-up
of 5.5 years. Mode of presentation was screening in 1007 (65.6%)
women. After adjustment for pathology screen detection had no
significant survival benefit: HR 0.73 (0.50–1.08, p = 0.116). Mode
of presentation had an independently significant interaction with
both nodal status and ER status (p = 0.003 and p = 0.01 respec-
tively). Further analysis demonstrated that screening was an
independent predictor of survival in the 1–3 node positive group
(HR 0.33 (0.15–0.73), p = 0.006); the ER positive group (HR 0.53
(0.31–0.89), p = 0.017) and in the moderate NPI group only (HR
0.54 (0.31–0.94), p = 0.030).
Conclusions: These results provide evidence of a significant
interaction between mode of presentation and pathology. Further
research is needed before incorporating mode of presentation
into decisions regarding adjuvant therapy.
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Epithelial proliferation has been used to determine therapy in
the St. Gallen guidelines (Ki67 P30% indicates the need for che-
motherapy). UK screen detected breast cancers (SDBC) (aged 50–
65 years) have an overall 97.2% 5 year relative survival compared
to 77.6% for symptomatic cancers.
To determine the value of Ki67 in post-menopausal breast
cancer in women aged 50–65 years, we have studied Ki67 in
1270 women with either symptomatic cancers (n = 412) or SDBC
(n = 858). Mean Ki67 in SDBC was 21.4 (SD 10.3) and 34.2 (SD
16.2) in symptomatic cancers (p = 60.001). For each 10 unit
increase in Ki67, increases in distant relapse occurred (RR 1.43:
95%CI; 1.32–1.55). Twelve per cent of symptomatic and 2% of SDBC
had died within 5 years.
Out of 458 women with Ki67 620, 27 died within 10 years
(93.2% survival) compared to 143 out of 775 with Ki67 P20%
(79% survival) (p = 60.001).
Ki67 was prognostic for symptomatic cancers of distant
relapse (p = 0.01) and mortality (p = 0.01) but was only predic-
tive of recurrence (p = 0.01) and not mortality in SDBC. In
SDBC, Ki67 values in the 2% who died did not differ from
those alive at 5 years and use of cut-off score of Ki67 of
P20% would have potentially selected 35% of women for che-
motherapy and a Ki67 of P30% would have potentially
selected 12% of women.
Epithelial proliferation is prognostic, but not predictive, of
chemotherapy benefit in SDBC.
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Background: Chemotherapy for treatment of breast cancer
has been increasingly used in neo-adjuvant setting to facilitate
pre-operative reduction in tumour size to make amenable to
surgery or to facilitate breast-conserving surgery in the place
of mastectomy. A complete pathological response to chemo-
therapy is associated with a greater overall and disease free
survival.
Purpose: This study aimed to identify molecular markers,
disease and treatment factors associated with complete patho-
logical response to neo-adjuvant chemotherapy in breast
cancer.
Methods: Fifty-six patients who received neo-adjuvant chemo-
therapy at our institution between January 2006 and January 2010
with complete histological information and definitive surgery at
the time of data collection were identified. Age, type, grade, cate-
gory of cancer, molecular markers including ER, PR, HER2, imag-
ing size, nodal status, chemotherapy regimen and pathological
response were recorded. Chi squared and Fisher Exact test were
used for statistical analysis.
Results: Eleven patients (19.6%) undergoing neo-adjuvant che-
motherapy had a complete pathological response and 6 patients
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